Although CD20-directed B cell depletion has long been used in neuromyelitis optica spectrum disorder (NMOSD), high-quality, large-scale, randomized controlled trials remain limited. In this multicenter, randomized, double-blind phase 3 trial, we evaluated obinutuzumab β (MIL62), a novel glycoengineered type II anti-CD2...
Lei Wu, Liangliang Gu, Wei-Hao Fan et al.· Nature Medicine· 1 citation
Background Complement activation plays a key role in the pathogenesis of neuromyelitis optica spectrum disorder (NMOSD). While eculizumab effectively prevents relapses, its role in acute attacks remains uncertain. Methods We retrospectively analyzed 38 patients with acute NMOSD treated with eculizumab across seven tert...
Tao Wu, De-Cai Tian, De-Hui Huang et al.· Frontiers in Immunology· 0 citations
Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis is a potentially severe autoimmune encephalitis that may rapidly progress to critical illness. We report a young patient with severe anti-NMDAR encephalitis complicated by seizures, psychiatric symptoms, behavioral disturbance, dyskinesia, and dysautonomia. Despit...
Yang Liu, Yu-Jing Yuan, Yingjie Zhang et al.· Journal of Neuroimmunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
